The fork in the road

Access to the next generation of antibody-like assets became more difficult last Friday when GlaxoSmithKline plc unveiled a £230 million ($455 million) bid for Domantis Inc., the developer of domain antibodies (dAbs), the smallest functional binding units of human antibodies. Domantis is still six months away from putting a dAb into patients.

"We were looking to get

Read the full 560 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE